New β-Lactam-β-Lactamase Inhibitor Combinations

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Rising antimicrobial resistance in Gram-negative bacilli necessitates novel therapeutic strategies.
• Limited existing treatments for infections caused by multidrug-resistant (MDR) Gram-negative bacteria.
• Development of beta-lactam-beta-lactamase inhibitor combinations (BLBLIs) as a promising approach.

Purpose of the Study:

• To review the in vitro activity, resistance mechanisms, and pharmacokinetic-pharmacodynamic (PK-PD) profiles of approved and investigational BLBLIs.
• To summarize available clinical data for these novel agents.
• To assess the potential of BLBLIs against challenging Gram-negative pathogens, including carbapenem-resistant strains.

Main Methods:

• Comprehensive literature review of published studies on BLBLIs.
• Analysis of in vitro susceptibility data against various Gram-negative bacilli.
• Evaluation of pharmacokinetic-pharmacodynamic (PK-PD) characteristics and clinical trial outcomes.

Main Results:

• Four approved BLBLIs (ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-relebactam) show activity against MDR Enterobacterales and Pseudomonas aeruginosa.
• Specific BLBLIs demonstrate efficacy against pathogens producing extended-spectrum beta-lactamases (ESBLs), carbapenemases (KPC), and AmpC.
• None of the reviewed drugs are active against metallo-beta-lactamase (MBL) producers or carbapenem-resistant Acinetobacter baumannii; however, several agents in development show promise.

Conclusions:

• Approved BLBLIs provide valuable treatment options for MDR Gram-negative infections, expanding the therapeutic armamentarium.
• Understanding resistance mechanisms and PK-PD is crucial for effective BLBLI utilization.
• Ongoing development of novel BLBLIs, including those targeting MBLs and carbapenem-resistant A. baumannii, offers future hope against highly resistant bacteria.